硝酸异山梨酯注射液配伍应用效果及安全性研究

Study on the efficiency and safety of isosorbide dinitrate in combination with meglumine cyclic adenylate and potassium megneim aspartate on unstable angina pectoris

目的探讨硝酸异山梨酯注射液(消心痛)治疗不稳定性心绞痛(UA)时配伍用药的效果和安全性。方法57例不稳定性心绞痛患者随机分为2组。硝酸异山梨酯联合用药组(n=27):硝酸异山梨酯联合环磷腺苷葡甲胺(心先安)、门冬氨酸钾镁(潘南金),静滴,每天1次,连续10d;对照组(n=30):给予常规UA治疗。比较治疗前后心绞痛发作及心电图所示的心肌缺血和心律失常的改善情况,同时对消心痛、心先安、潘南金的配伍用药进行研究。结果硝酸异山梨酯联合用药组心绞痛发作频率减少,间隔时间延长,心率较治疗前减慢,与对照组比较均存在明显差异(P<0.01)。心电图ST段下移虽有抬高,但无统计学差异(P>0.05)。以上3种药物没有配伍禁忌。结论硝酸异山梨酯联合心先安和潘南金可以改善心肌缺血,减轻冠状动脉痉挛,减少心律失常的发生,副作用很少。

Objective To investigate the efficacy and safety of drug compatibility of Isosorbide Dinitrate(ISD), Meglumine cyclic adenylate(MCA)and Potassium Magnesium Aspartate(PMA)in the patients with unstable angina pectoris (UA). Methods Fifty-seven cases of UA were randomly divided into the ISD plus group(the treatment group, n=27) treated with the above three drugs and the control group (n=30) in which the patients were routinely treated. The improvements on the attack of angina pectoris, the ischemic cardiac muscle and cardiac muscle disorder shown in the cardiogram before and after the treatment were compared. The drug compatibility of Isosorbide Dinitrate, Meglumine cyclic adenylate and Potassium Magnesium Aspartate were studied. Results The incidence of angina pectoris was decreased and its interval prolonged. The patients’ heart rate was slower than before. All of the parameters were significantly different to those in the control group (P<0.01). Also the ECG revealed that the descended S-T segments restored, but there was no statistical difference (P>0.05). There was no compatibility taboo in the three drugs. Conclusions Isosorbide Dinitrate with Meglumine cyclic adenylate and Potassium Megneim Aspartate can improve myocardial ischemia, diminish coronary artery spasm and decrease the incidence of arrhythmia without matching reaction and with rare side effects.